CRIS Current Research Information System

BROCCOLI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.908
AS - Asia 6.143
EU - Europa 5.983
SA - Sud America 435
AF - Africa 368
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 19.846
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.824
SG - Singapore 1.987
CN - Cina 1.886
IT - Italia 1.079
VN - Vietnam 1.030
DE - Germania 1.013
GB - Regno Unito 927
NL - Olanda 845
SE - Svezia 839
HK - Hong Kong 489
BR - Brasile 333
RU - Federazione Russa 305
IN - India 283
KR - Corea 205
FR - Francia 203
IE - Irlanda 188
UA - Ucraina 150
TG - Togo 108
FI - Finlandia 93
CI - Costa d'Avorio 92
ZA - Sudafrica 91
EE - Estonia 72
JP - Giappone 61
PL - Polonia 56
AR - Argentina 51
JO - Giordania 51
CA - Canada 47
ID - Indonesia 41
AT - Austria 36
CH - Svizzera 33
SC - Seychelles 33
NG - Nigeria 31
BE - Belgio 26
ES - Italia 26
MX - Messico 26
HR - Croazia 23
IR - Iran 20
BG - Bulgaria 17
EC - Ecuador 13
BD - Bangladesh 12
TR - Turchia 11
IQ - Iraq 9
LB - Libano 9
LT - Lituania 9
PY - Paraguay 9
CL - Cile 7
PE - Perù 7
RO - Romania 7
VE - Venezuela 7
MY - Malesia 6
PT - Portogallo 6
RS - Serbia 6
CZ - Repubblica Ceca 5
EG - Egitto 5
PK - Pakistan 5
UZ - Uzbekistan 5
AU - Australia 4
GR - Grecia 4
IL - Israele 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CO - Colombia 2
DK - Danimarca 2
DZ - Algeria 2
HU - Ungheria 2
KW - Kuwait 2
MK - Macedonia 2
PA - Panama 2
QA - Qatar 2
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
ET - Etiopia 1
GI - Gibilterra 1
KG - Kirghizistan 1
KH - Cambogia 1
LC - Santa Lucia 1
MA - Marocco 1
MN - Mongolia 1
MU - Mauritius 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
PW - Palau 1
RE - Reunion 1
Totale 19.843
Salva come PNG Salva come JPEG
Città #
Singapore 1.307
Ashburn 795
Southend 782
Fairfield 719
Kerkrade 666
Chandler 551
Hong Kong 486
Hefei 450
Santa Clara 382
Houston 379
Frankfurt am Main 378
Woodbridge 369
Seattle 312
Wilmington 290
Dong Ket 278
Beijing 260
Princeton 241
Ann Arbor 237
Cambridge 223
Seoul 205
Bologna 204
Dublin 188
Boardman 182
Ho Chi Minh City 159
Dallas 111
Hanoi 110
Los Angeles 110
Lomé 108
New York 104
Milan 99
Abidjan 92
Berlin 91
Westminster 87
Nanjing 84
Padova 71
Jinan 67
Helsinki 65
Buffalo 59
Tokyo 58
Bremen 54
Rome 54
Jacksonville 52
Amman 51
Shenyang 48
London 46
Bengaluru 43
Turin 43
Warsaw 43
San Diego 42
Saint Petersburg 40
Secaucus 40
Changsha 39
Redondo Beach 39
Falkenstein 38
São Paulo 36
Shanghai 35
Hebei 34
Zhengzhou 33
Dearborn 32
Munich 32
Kyiv 31
Nanchang 31
Chicago 29
Hangzhou 29
Hyderabad 29
Redwood City 29
Abeokuta 28
Florence 28
Tianjin 28
Des Moines 27
Guangzhou 27
Jakarta 26
Phoenix 26
Jiaxing 25
Toronto 25
Bern 24
Brussels 24
Redmond 22
Düsseldorf 21
Lappeenranta 21
Nuremberg 21
Orem 18
Olalla 17
Fuzhou 16
Haiphong 16
Yubileyny 16
Amsterdam 15
Falls Church 15
Modena 15
Vienna 15
Brooklyn 14
Shenzhen 14
Tongling 14
Da Nang 13
Ningbo 13
Sofia 13
Taiyuan 13
Taizhou 13
Verona 13
Catania 12
Totale 13.059
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 1.449
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 380
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets 248
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 226
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 226
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 216
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 207
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 205
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 202
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 195
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 195
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 189
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 187
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 185
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 184
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 183
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 181
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 179
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 175
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 175
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 172
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 171
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 170
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 169
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 165
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 163
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 163
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 163
Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. 158
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 155
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 152
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 152
Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature 151
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 151
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 150
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 148
Hepato-gastric and spleno-mesenteric arterial trunks: anatomical variation report and review of literature 148
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 148
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 147
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 146
Angioimmunoblastic T-Cell Lymphoma 146
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 146
Living Anatomy 145
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 145
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 144
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 144
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 144
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 143
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 143
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 141
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 141
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 139
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 138
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 137
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 136
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 136
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 135
Cutaneous adverse-events in patients treated with Ibrutinib 134
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 133
The Prognostic value of tumor and microenvironment markers in classifical Hodgkin lymphoma (CHL) patients. 132
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 132
Corso di malattie del sangue e degli organi emolinfopoietici 130
Hepatogastric and splenomesenteric arterial trunks: anatomical variations report 129
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 128
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 128
Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report 128
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 128
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 127
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 126
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. 126
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 126
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified (Modern Pathology, (2020), 33, 2, (179-187), 10.1038/s41379-019-0279-8) 125
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 125
Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. 124
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 124
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab 124
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 124
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 123
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease 122
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 122
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor 120
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 120
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 119
Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma 119
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 119
Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukaemia patients 118
The unique biology and treatment of primary mediastinal B-cell lymphoma 118
The prognostic value of biologic markers in classical hodgkin lymphoma (CHL) patients. 117
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 116
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 116
Erythematous induration of the chest 115
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. 115
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib 113
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. 113
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 112
Genetic and phenotypic attributes of splenic marginal zone lymphoma 111
Possible novel agents in marginal zone lymphoma 111
Primary Bone Lymphoma: Evaluation odf Chemoimmunotherapy as Front-line Treatment in 21 Patients 109
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 108
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 107
Totale 16.148
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.538
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.538
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.156 0 0 0 0 0 66 28 65 210 51 66 670
2021/20222.125 211 60 122 258 187 110 37 159 74 153 424 330
2022/20232.566 237 371 171 333 213 204 60 191 397 85 162 142
2023/2024889 66 156 76 104 67 113 55 53 28 71 40 60
2024/20254.018 174 497 327 259 567 176 439 121 97 293 213 855
2025/20265.514 748 988 795 635 912 1.436 0 0 0 0 0 0
Totale 20.280